ERBB2 and breast carcinoma: Just as ERBB2, PI3KCA, ESR1, and other genes have guided the selection of breast cancer treatment strategies, TP53 mutations, with their high mutation rate and value in predicting anti‐HER2 treatment response, will certainly play a role in precision therapy in the future and become very valuable therapeutic biomarkers in clinical practice.4, 25, 26